Pentasa Sachets licensed for paediatric use

Pentasa Sachets (mesalazine) are now licensed for use in children with mild to moderate ulcerative colitis, from the age of 6 years.

As a general rule, half the adult dose may be given to children up to a body weight of 40kg, and the normal adult dose to those weighing more than 40kg.

Pentasa Sachets were previously contraindicated under the age of 12 years. The only other mesalazine preparation currently available for use in children is Salofalk Granules.

View Pentasa drug record

Further information: Ferring Pharmaceuticals

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

First oral GLP-1 agonist launched for type II diabetes

First oral GLP-1 agonist launched for type II diabetes

Prescribers can now consider a GLP-1 agonist as an...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Don't prescribe analgesics for chronic pain, new NICE guidance advises

Don't prescribe analgesics for chronic pain, new NICE guidance advises

Draft NICE guidance on chronic pain warns that prescribing...